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Abstract
Background: Greater transparency and, in particular, sharing of clinical study reports and patient level data for
further research is an increasingly important topic for the pharmaceutical and biotechnology industry and other
organisations who sponsor and conduct clinical research as well as academic researchers and patient advocacy
groups. Statisticians are ambassadors for data sharing and are central to its success. They play an integral role in
data sharing discussions within their companies and also externally helping to shape policy and processes while
providing input into practical solutions to aid data sharing. Data sharing is generating changes in the required
profile for statisticians in the pharmaceutical and biotechnology industry, as well as academic institutions and
patient advocacy groups.
Discussion: Successful statisticians need to possess many qualities required in today’s pharmaceutical environment
such as collaboration, diplomacy, written and oral skills and an ability to be responsive; they are also knowledgeable
when debating strategy and analytical techniques. However, increasing data transparency will require statisticians to
evolve and learn new skills and behaviours during their career which may not have been an accepted part of the
traditional role. Statisticians will move from being the gate-keepers of data to be data facilitators. To adapt successfully
to this new environment, the role of the statistician is likely to be broader, including defining new responsibilities that
lie beyond the boundaries of the traditional role. Statisticians should understand how data transparency can benefit
them and the potential strategic advantage it can bring and be fully aware of the pharmaceutical and biotechnology
industry commitments to data transparency and the policies within their company or research institute in addition to
focusing on reviewing requests and provisioning data.
Summary: Data transparency will evolve the role of statisticians within the pharmaceutical and biotechnology industry,
academia and research bodies to a level which may not have been an accepted part of their traditional role or career.
In the future, skills will be required to manage challenges arising from data sharing; statisticians will need strong
scientific and statistical guiding principles for reanalysis and supplementary analyses based on researchers’ requests,
have enhanced consultancy skills, in particular the ability to defend good statistical practice in the face of criticism
and the ability to critique methods of analysis. Statisticians will also require expertise in data privacy regulations, data
redaction and anonymisation and be able to assess the probability of re-identification, an ability to understand analyses
conducted by researchers and recognise why such analyses may propose different results compared to the original
analyses. Bringing these skills to the implementation of data sharing and interpretation of the results will help to
maximise the value of shared data while guarding against misleading conclusions.
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Background
This article is one of a series of articles developed by the
EFSPI (European Federation of Statisticians in the
Pharmaceutical Industry) [1] and PSI (Statisticians in the
Pharmaceutical Industry) [2] Data Sharing Working
Group. The Working Group consists of medical research
statisticians from the pharmaceutical and biotechnology
industries and academia, with the intention of providing
knowledge and insights regarding the practical chal-
lenges and opportunities of accessing research data for
re-analysis or secondary research purposes.
The intended audience for this article comprises par-
ties interested in the value statisticians can add to the
topic of data sharing within the pharmaceutical or bio-
technology industries and academic research groups.
Also for statisticians whose role may evolve due to data
transparency, this paper intends to highlight areas and
skills statisticians may not have considered as part of
their role.
Prior to the introduction of EMA policy 0070 [3] on
data sharing, a statistician’s role in accessing external
data would have been limited to gleaning information on
other companies’ results from published manuscripts or
from websites such as www.clinicaltrials.gov. Following
the introduction of the EMA policy 0070 the subject has
become embedded in the culture of large pharmaceutical
and biotechnology companies, and longstanding aca-
demic trials units; although, perhaps due to resource
constraints or fewer opportunities, to a lesser extent in
some small companies and certain academic research
groups. However, this is a continually evolving area. For
many years, large pharmaceutical and biotechnology
companies have had policies in place regarding access to
Clinical Study Reports (CSRs); the EMA draft policy
0070 on data sharing prompted the industry into creat-
ing further policies to address the sharing of individual
patient level data (IPD) from clinical trials they con-
ducted. Whilst EMA policy 0070 makes reference to
sharing of IPD, there is currently no regulatory mandate
to do so. The majority of pharmaceutical and biotech-
nology companies have responded positively to this call
for increased transparency believing it’s a positive step
for industry, researchers and the public. In 2014, the
PhRMA/EFPIA (Pharmaceutical Research and Manufac-
turers of America, European Federation of Pharmaceutical
Industries and Associations) ‘Principles for Responsible
Clinical Trial Sharing’ stated a commitment to enhancing
public health through responsible sharing of clinical trial
data in a manner that is consistent with principles to safe-
guard the privacy of patients, respecting the integrity of
national regulatory systems, and maintaining incentives
for investment in biomedical research. Implementation
started in January 2015 of five specific commitments to
enhance data sharing with researchers, enhance public
access to clinical study information, share results with pa-
tients who participate in clinical trials, certify procedures
for sharing clinical trial information, and reaffirmation
of commitments to publish clinical trial results. Data
sharing has also provoked an unprecedented collabor-
ation between companies with such initiatives as the
Multi-User Clinical Study Data Request (CSDR) Plat-
form (www.clinicalstudydatarequest.com) which con-
tinues to develop and increase in subscribers. The
platform was developed by large pharmaceutical compan-
ies (initiated by GlaxoSmithkline) with the view that this
could become a viable platform for all data holders, i.e.,
large, medium and small companies and, potentially,
academic institutions. To date, only pharmaceutical and
biotechnology companies have signed up, however, there
are other models under discussion with institutes such as
the Multi-Region Clinical Trials (MRCT) Center of
Harvard and Brigham and Women’s Hospital who advo-
cate a centralised single-platform with the ability to up-
load and download data with the capability to grow and
add data from new sponsors [4].
Statisticians are ambassadors for data sharing and are
central to its success. They play an integral role in data
sharing discussions within their respective companies
and also externally helping to shape policy and processes
while providing input into practical solutions to aid data
sharing. Secondary use of data is implicit in public-
sector trials, and access to data is aligned with the values
of many pharmaceutical and biotechnology companies
related to benefits to society and patients; some com-
panies and individuals remain cautious regarding the
benefits and sceptical of how the data will be used in
particular where there is the potential to make un-
founded health scares involving their assets.
Traditionally, the roles and responsibilities of a
statistician have tended to be focussed on providing stra-
tegic input to pre-clinical research, clinical development
plans, designing clinical trials, generating clinical evi-
dence to support regulatory submissions, reimbursement
submissions (payers) and publications as well as sup-
porting post-marketing activities [5]. In general, discus-
sions with external parties regarding analysis methods
and inferences have tended to focus on formal requests
from regulatory agencies and reimbursement agencies,
and responding to peer review comments from submit-
ted manuscripts. In contrast, statisticians in academic in-
stitutions have focussed on publications with a strong
desire to access data retained by pharmaceutical and
biotechnology companies. To date, for the majority of
statisticians, there has been little time spent collaborat-
ing between pharmaceutical and biotechnology compan-
ies and other (e.g. academic) research organizations in
terms of data sharing. However with a future trend to-
wards greater transparency, building public trust and
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increased data sharing, engagement between these stake-
holders will increase.
Statisticians possess many qualities such as negoti-
ation, collaboration, diplomacy, written and oral skills
and an ability to be responsive and knowledgeable when
debating analytical techniques; however data transpar-
ency will require the majority of statisticians from
industry to learn new skills and ways of working. If not
already engaged with external activities, statisticians
within the pharmaceutical and biotechnology industry
and academia will increasingly expand their role to be-
come more embedded in the data facilitation process.
To adapt successfully to this new environment, statistical
leaders within the pharmaceutical and biotechnology
industries and academia will work towards broadening
the role of the statistician, and define new responsi-
bilities that lie beyond the normal boundaries. Build-
ing trust with the public through greater transparency
and increased engagement with academic researchers
will bring many benefits, but these will inevitably
come at a cost in terms of time and resources, which
will be particularly acute for smaller companies, and
will require commitment from industry leaders to ad-
dress these demands.
Discussion
Overview on anticipated changes
Data sharing is generating changes to the traditional role
of a statistician within the pharmaceutical and biotech-
nology industry, as well as academic institutions. This
will affect a number of areas of their work including: 1)
An understanding of what data transparency can offer
statisticians, 2) An increased ability to rapidly under-
stand other study designs and analytical techniques, 3)
More thorough documentation of analysis methods and
data manipulation, 4) An increased focus on being able
to utilize opportunities of data sharing to benefit their
own work and the ability to understand and replicate
analyses conducted by other researchers, 5) An in-
creased focus on consultancy skills and a collaborative
attitude to manage an external network, and 6) Expertise
in re-analysing data with modern analytical techniques.
Opportunities for how the role of statisticians may
evolve with increased sharing of clinical trial data are
discussed.
What can data transparency offer statisticians?
As well as focusing on requests for data, statisticians
should understand how data transparency can benefit
them and the potential strategic advantage it can bring,
be fully aware of the pharmaceutical and biotechnology
industry commitments to data transparency, and the
policies within their company or research institute. Since
discussion started in relation to data transparency the
focus has been on academic researchers requesting data
from pharmaceutical or biotechnology companies; but
what of the reverse scenario where pharmaceutical/
biotechnology industry statisticians request data from
academic researchers or other pharmaceutical/biotech-
nology companies? Although this is possible, to date
we are not aware of a company requesting IPD gener-
ated through a clinical trial conducted by another
company. Some have requested CSRs as these com-
pany policies have been in place for a number of
years. However, we consider this to be a matter of
time where in the future the sharing of data between
companies will be the norm alongside the increasing
number of research collaborations. Thus, statisticians
in the pharmaceutical industry may become exposed
to an academic-like working style, with regard to as-
pects such as the interpretation of data from other
researchers. This may be a further opportunity for
statisticians to be valued as strategic thinkers. Access
to additional external data will have advantages aiding
the design of studies. For example, it will help to
understand patterns of missing data, predicting drop-
outs, provide good prior distributions and aid in pre-
dicting study success, etc.
Study design and implementation
Pharmaceutical and biotechnology companies might be
inclined to align on optimal study designs and the cor-
rect data to be collecting. Linking in with core datasets
initiatives such as COMET (Core Outcome Measures in
Effectiveness Trials; www.comet-initiative.org) will be-
come important for statisticians. The COMET Initiative
brings together people interested in the development
and application of agreed standardised sets of outcomes,
known as ‘core outcome sets’. These sets represent the
minimum that should be measured and reported in all
clinical trials of a specific condition, and are also suitable
for use in clinical audit or research other than rando-
mised trials. There is an expectation that the core out-
comes will be collected and reported, making it easier
for the results of trials to be compared, contrasted and
combined as appropriate.
Thorough documentation of analysis methods and data
manipulation
Key to the success of data sharing will be thorough and
accurate documentation of analysis methods and data
manipulation techniques. A statistician produces an ana-
lysis plan documenting the analysis techniques and also
documents any data manipulations required to convert
data from that collected and entered into the database
into data which is analytically useable; the only industry
standards in place to do this are from the Clinical Data
Interchange Standards Consortium (CDISC) for converting
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raw data to the Study Data Tabulation Model (SDTM);
SDTM is a documented standard in the Pharmaceutical
Industry for converting raw data into a standardised format
which should be more analytically useable though may re-
quire more effort for the user to understand. The quality of
documentation produced within the industry varies consid-
erably, particularly relating to the conversion from SDTM
to Analysis Data Model (ADaM) datasets; ADaM datasets
are considered analysis-ready by the pharmaceutical indus-
try. It would be naïve to suggest a statistician, without
knowledge of a company or research group’s processes, or
knowledge of CDISC could reliably reproduce the analysis
of a clinical trial. Generally, the pharmaceutical/biotechnol-
ogy industry will document data manipulations using statis-
tical programming code (e.g. SAS, R) in a spreadsheet or
database, but this will mean very little to a researcher un-
familiar with the statistical programming language used. In
academic and small pharmaceutical or biotechnology com-
panies, the level of documentation is likely to be less and
data manipulation unlikely to be using CDISC standards
for SDTM due to knowledge and resources. In fact, know-
ledge of SDTM and terminology may not exist in these set-
tings. Clearly the data requestor will need to understand
the data and statistical methodology before undertaking
their research and the data holder should thoroughly docu-
ment this. Communication and clear documentation will
be needed between data holders and researchers along with
further collaboration and more industry standards and best
practices. In some cases a company or research institute,
may use a Contract Research Organisation (CRO) which
introduces a third party into the communication chain; a
thorough understanding of roles and responsibilities will
need to be further assessed under these circumstances.
Irrespective of the problems related to documenting
data manipulation, there are additional questions to con-
sider. Can an analysis plan be followed accurately enough
to reproduce an analysis? Is a CSR the correct place to
document deviations from an analysis plan? Furthermore,
how are analyses potentially un-documented in the CSR,
e.g., additional analyses required for manuscripts, reim-
bursement dossiers, etc. to be documented? The statisti-
cian generating these analyses may not be associated with
the company or research institute when the data request
is received and therefore it is critical to document analyt-
ical decisions at the point of its conception and/or
completion. Understandably there will always be some
scepticism of how the data has been manipulated and
whether the data has been deployed in such a way as to
bias the results towards the primary objectives and alter-
native hypotheses. But equally, statisticians are also
inclined by training towards accepting the null hypothesis
to be “true” unless there is significant evidence to the
contrary. Additionally statistician’s training is to reduce
bias without compromise and all pharmaceutical/
biotechnology statisticians work in a heavily regulated en-
vironment where any analytical technique or data ma-
nipulation is open to scrutiny by international and pan-
European agencies. Therefore, data transparency should
reduce the external scepticism as researchers become
more confident in the quality of industry’s analyses and
data manipulation processes; we are seeing this to a cer-
tain extent already. For example, In 2005 JAMA adopted a
policy that included a requirement for independent statis-
tical analysis by an academic biostatistician for industry-
sponsored and industry-analysed studies due to several
high-profile trials that had evidence of problems with data
integrity, inappropriately conducted statistical analyses,
and incomplete reporting of major findings. In 2013,
JAMA changed their policy to consider, for publication,
clinical trials that are analysed by statisticians employed
by or contracted by the study sponsor, without requiring
independent statistical analysis by an academic biostatisti-
cian. JAMA found that over the previous two years, the
conduct of additional analyses by independent academic
biostatisticians generally did not result in meaningful
changes in the study results [6].
Increased technical skills
External collaboration will necessitate statisticians to
have the ability to understand and replicate analyses
conducted by other researchers. Although there are
many statisticians already undertaking such research and
discussions, an increased number of statisticians will be
required to have expertise in reviewing and interpreting
systematic reviews and meta-analyses, to conduct evalu-
ations of methods used, and to provide a response where
methods may be flawed or lead to false conclusions. An
open-minded approach is needed requiring research into
different statistical methods in order to fully understand
the research that has been conducted.
Statistical methods continually evolve with innovation or
in reaction to specific challenges, sometimes made possible
only with modern computational power, and a researcher
may want to conduct an investigation using a more power-
ful method than that used in the primary analysis. If the
conclusions differ, the reaction from the data-holder may
be to defend the original analysis. Rather than a culture of
defending the original analysis as being correct, and fearing
that an alternative analysis may give a different conclusion,
statisticians should foster a spirit of openness and curiosity
particularly where methods are potentially more advanced.
If the conclusions are not robust, in terms of different ana-
lysis methods, then statisticians should examine what as-
sumptions are being made, and explore any inconsistencies.
Data management expertise
Statisticians have played major roles in defining IPD sys-
tems and process development such as CSDR while also
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shaping policies related to access to clinical trial data.
Statisticians can leverage their experience as data access
experts with regard to data sharing both internal and ex-
ternal to their employer. External data sharing is about
providing access to data but also provides a support
mechanism around data structure and advice on poten-
tial analyses. Openness and a strong collaborative atti-
tude are significant attributes required for data sharing
to be successful in order to minimise the risk of publica-
tion of misleading results.
Data redaction and anonymisation
Technical advances will not only be statistical. Statisti-
cians will probably be the primary contact for data
redaction and anonymisation requiring significant know-
ledge of data privacy legislation along with relevant guid-
ance documents [7–15]. To understand the data, a
researcher may attempt to reproduce the primary ana-
lysis of a study. This can prove difficult in certain situa-
tions depending on the anonymisation technique. For
example, one potential technique for maintaining anon-
ymisation is to move dates by a random number of days
or replace dates with days from randomization or first
dose. Reproducing analyses in these situations is gener-
ally easily facilitated but that is not the case in situations
where diseases are seasonal, e.g., asthma or allergies
such as hay fever. Furthermore, informed consent con-
siderations may lead to all patients from selected
countries being removed prior to data being shared.
Statisticians will need technical knowledge to under-
stand the analysis methods balanced with data privacy
requirements to minimise the probability of re-
identification. In terms of re-identification of redacted
data in a CSR and IPD, in the future there is likely to be
an expectation that a company statistician makes an esti-
mation of the probability of an individual being re-
identified.
Consultancy skills
When the data sharing models (e.g. CSDR, Yale Univer-
sity Open Data Access [YODA; www.yoda.yale.edu])
were put in place it was a deliberate requirement by the
pharmaceutical and biotechnology industries to maintain
the independence of the data-requestor with no influ-
ence from the data sharer in receiving, reviewing, or
approving data sharing requests. However, some data
sharing models have been set up to allow collaboration
between the data holder and researchers requesting
access to data. Independence has been maintained, al-
though it has been possible for some contact between
the researcher and data-holder to respond to questions
related to the data and analytical technique. However,
there is the potential for data sharing to be more collab-
orative. For this to be successful, core competencies for
statisticians will include strong written and oral commu-
nication skills, which although accepted as a require-
ment now, will need to be of an alternative style when
collaborating with external researchers with a low em-
phasis on individual company communication styles and
a higher importance on language understandable be-
tween multiple communities. In addition, collaboration
skills, especially with academia, and an ability to react to
different opinions will be required. This includes an abil-
ity to be responsive to requests, to listen and learn, and
to supplement strong analytical skills with the ability to
engage openly with external researchers. Academic re-
searchers may be seeking answers to different questions
compared to regulators and payers, and researchers may
have very different objectives compared to those of the
clinical development plan for a product. For example,
researchers may be more concerned with defining
clinically-relevant outcomes at the individual patient
level, rather than looking at population-based averages
which are often the focus of clinical research supporting
regulatory submissions. Where differences of opinions
do occur it is important to follow good scientific and
statistical principles, and be mindful that the ultimate
focus of all clinical research should be on patients.
As CSRs become widely available, a more intensive re-
view and critique of CSRs will bring more questions
from research and patient groups. As a reaction, com-
panies will be more careful in the interpretation of re-
sults within the CSR and reduce interpretations to the
minimum demanded by the objectives of the study. This
may make CSRs also increasingly straight forward to in-
terpret from a statistical point of view. Requests from re-
searchers to sponsors have primarily focused on data
provision, but in the future more collaboration on add-
itional analyses beyond the CSR content will be needed
rather than a request for the IPD itself. Being able to dis-
cuss questions posed by researchers will require statis-
tical support and the statistics departments should be
prepared for this.
Summary
Data transparency will lead to some changes within the
pharmaceutical and biotechnology industry as well as
academia and other research bodies. The majority of
those parties are overwhelmingly supportive and believe
future research will build trust between associations and
will be of benefit to patients. The typical role of all stat-
isticians within the pharmaceutical and biotechnology
industries, academia and research bodies will require ad-
aptations over time.
Key areas of expertise required by statisticians cur-
rently include: Strong collaborative skills, good written
and oral communication skills, an ability to listen and be
responsive to requests from colleagues and expertise in
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explaining the appropriateness of statistical methods of
analysis.
In the future additional skills will be required to man-
age opportunities arising from data sharing to a level
which may not have been an accepted part of their trad-
itional role or career. Statisticians will need to be fully
aware of the pharmaceutical and biotechnology industry
commitments to data transparency and the policies
within their company or research institute and have
strong scientific and statistical technical skills applicable
to supplementary analyses as part of any collaboration
with other researchers. They will also require enhanced
consultancy skills, in particular the ability to defend
good statistical practice in the face of criticism and the
ability to critique methods of analysis. While also having
expertise in data privacy regulations, data redaction and
anonymisation and be able to assess the probability of
re-identification, statisticians will also need an ability to
understand analyses conducted by researchers and rec-
ognise why such analyses may propose different results
compared to the original. Bringing these skills to the im-
plementation of data sharing and interpretation of the
results will help to maximise the value of shared data
while guarding against misleading conclusions.
Abbreviations
ADaM, analysis data model; CDISC, clinical data interchange standards
consortium; COMET, core outcome measures in effectiveness trials; CRO,
contract research organization; CSDR, clinical study data request; CSR, clinical
study report; EFPIA, European Federation of Pharmaceutical Industries and
Associations; EFSPI, European Federation of Statisticians in the
Pharmaceutical Industry; EMA, European Medicines Agency; FDA, Food and
Drug Administration; ICH, International Council for Harmonisation; IPD,
individual patient data; ITT, Intent-to-Treat; JAMA, Journal of the American
Medical Association; MA, meta-analysis; MRCT, multi-region clinical trials;
NMA, network meta-analysis; PhRMA, Pharmaceutical Research and
Manufacturers of America; PSI, Statisticians in the Pharmaceutical Industry;
SAP, statistical analysis plan; SDTM, study data tabulation model; STRATOS,
strengthening analytical thinking for observational studies; YODA, Yale
University Open Data Access.
Declarations
Publication of this article was funded by Amgen Ltd.
This article has been published as part of BMC Medical Research Methodology
Vol 16 Suppl 1, 2016: Data sharing in pharma. The articles have been through
the journal’s standard peer review process for supplements. The full content of
the supplement can be found at http://bmcmedresmethodol.biomedcentral.
com/articles/supplements/volume-16-supplement-1.
Acknowledgments
We acknowledge and thank those members of EFSPI and PSI who have
contributed to the discussions and participating in the review of the data
sharing publications, particularly Ursula Becker, Caroline Whatley-Smith,
Chrissie Fletcher, Janice Branson, Katherine Tucker, Maria Dilleen, and Zoe
Williams.
Authors’ contributions
SH and H-UB were co-leads of the EFSPI/PSI data transparency working
group which conceived the plan for this manuscript. All authors helped to
draft the manuscript and read and approved the final manuscript.
Competing interests
Nick Manamley, Steve Mallett, Sally Hollis, Alison Scrimgeour, Hans Ulrich
Burger, and Hans-Joerg Urban are currently or previously employed in the
pharmaceutical industry as indicated in their affiliations. Amgen Ltd. paid the
article-processing charge. Matthew R Sydes has received educational grants
and drug to support academic-led clinical trials. The authors declare that
they have no competing interests.
Author details
1Amgen Ltd., 240 Cambridge Science Park, Cambridge CB4 0WD, UK.
2GlaxoSmithkline, Stockley Park West, 1-3 Ironbridge Road, Uxbridge,
Middlesex UB11 1BT, UK. 3MRC Clinical Trials Unit at UCL, Institute of Clinical
Trials & Methodology, London, UK. 4MRC London Hub for Trials
Methodology, Aviation House, 125 Kingsway, London WC2B 6NH, UK.
5AstraZeneca, Alderley Park, Cheshire SK10 4TG, UK. 6Centre for Biostatistics,
Institute of Population Health, University of Manchester, Manchester
Academic Health Science Centre, Oxford Road, Manchester M13 9PL, UK.
7Vectura, One Prospect West, Chippenham, Wiltshire SN14 6FH, UK.
8Hoffman-La Roche, Grenzacherstrasse 124, Basel 4070, Switzerland.
Published: 8 July 2016
References
1. European Federation of Statisticians in the Pharmaceutical Industry https://
www.efspi.org/EFSPI/About_EFSPI/Working_Groups/EFSPI/About_EFSPI/
Working_Groups.aspx Accessed 20 Aug 2015.
2. Statisticians in the Pharmaceutical Industry http://www.psiweb.org/
Accessed 20 Aug 2015.
3. European Medicines Agency policy on publication of clinical data for
medicinal products for human use. http://www.ema.europa.eu/docs/en_GB/
document_library/Other/2014/10/WC500174796.pdf. Accessed 20 Aug 2015.
4. http://mrctcenter.org/news/committed-leaders-gather-drive-clinical-trial-
data-transparency-solutions. Accessed 20 Aug 2015.
5. Future roles and opportunities for statisticians in pharmaceutical industry;
https://www.efspi.org/documents/publications/
futurerolesforstatisticiansinpharmaceuticalindustrybjv5.PDF. Accessed 20 Aug
2015.
6. Howard B. Editorial Policies for Clinical Trials and the Continued Changes in
Medical Journalism. JAMA. 2013;310(2):149–50. doi:10.1001/jama.2013.8083.
7. European Federation of Pharmaceutical Industries and Associates (EFPIA) –
PhRMA. Principles for Responsible Clinical Trial Data Sharing: Our




8. US Office for Civil Rights (OCR). Guidance Regarding Methods for De-
identification of Protected Health Information in Accordance with the
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. 26
Nov 2012. http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/
De-identification/hhs_deid_guidance.pdf. Accessed 20 Aug 2015.
9. Shostak J. De-Identification of Clinical Trials Data Demystified. http://www.
lexjansen.com/pharmasug/2006/publichealthresearch/pr02.pdf. Accessed
20 Aug 2015.
10. European Commission. Clinical Trials Regulation (EU) No 536/2014. 2014.
http://ec.europa.eu/health/human-use/clinical-trials/regulation/index_en.
htm. Accessed 20 Aug 2015.
11. European Parliament and Council: Regulation (EC) No 45/2001 of the
European Parliament and of the Council on the protection of 61 individuals
with regard to the processing of personal data by the Community
institutions and 62 bodies and on the free movement of such data (18
December 2000).http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:
2001:008:0001:0022:en:PDF. Accessed 20 Aug 2015.
12. European Parliament and Council: Directive 95/46/EC of the European
Parliament and of the Council on the protection of 64 individuals with
regard to the processing of personal data and on the free movement of
such 65 data (24 October 1995). http://eur-lex.europa.eu/LexUriServ/
LexUriServ.do?uri=CELEX:31995L0046:en:HTML. Accessed 20 Aug 2015.
13. The Working Party on the Protection of Individuals with regard to
the Processing of Personal Data. Article 29 Data Protection Working
Party. WP216. Opinion 05/2014 on Anonymisation Techniques. 10 Apr
2014. http://ec.europa.eu/justice/data-protection/article-29/
Manamley et al. BMC Medical Research Methodology 2016, 16(Suppl 1):75 Page 42 of 43
documentation/opinion-recommendation/files/2014/wp216_en.pdf.
Accessed 20 Aug 2015.
14. El Emam K, Álvarez C. A critical appraisal of the Article 29 Working Party
Opinion 05/2014 on data anonymization techniques. Int Data Privacy Law.
2015;5:73–87. doi:10.1093/idpl/ipu033.
15. U.S. Department of Health and Human Services. Code of Federal
Regulations. Title 45. Public Welfare. Part 46 Protection of Human Subjects.
15 Jan 2009. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.
html. Accessed 20 Aug 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Manamley et al. BMC Medical Research Methodology 2016, 16(Suppl 1):75 Page 43 of 43
